OVM-200 Phase 1 Clinical Trial featured on TV

The OVM-200 Phase 1 Clinical Trial at The Christie in Manchester was featured on ITV’s Granada News on Wednesday 7th September 2022. It is a first-in-class of ROP cancer vaccine in human clinical trial. ROP therapeutic vaccines will provide additional options for the treatment of cancer patients. Professor Shisong Jiang , Chief Scientific Officer and Founder of OVM said: We see the potential benefits of a vaccination approach both in stimulating the body’s immune system to attack the cancer and also, in future trials, enhancing the efficacy of other immune-oncology agents. This Phase I trial is a first step towards having effective cancer vaccines. Read the full article and watch the video report here: Chorley mum with ovarian cancer first in North West to get new vaccine trialled at the Christie

The release as fetched from its publisher. oxfordvacmedix.com ↗